CollPlant Biotechnologies Ltd - ADR

CollPlant Biotechnologies Ltd. operates as a regenerative and aesthetic medicine company. It engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. Its products include VergenixSTR, VergenixFG, and Collink.3D. The company was founded by Oded Shoseyov in June 2004 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CollPlant Biotechnologies Ltd (NASDAQ:CLGN ) Q3 2024 Earnings Conference Call November 27, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Operator Greetings, and welcome to the CollPlant Biotechnologies Third Quarter 2024 Earnings Call. At this time all participants are in a listen-only mode.

CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript

Stratasys

- Promising results obtained from the pre-clinical study with CollPlant's commercial sized rhCollagen-based regenerative breast implants, demonstrating significant implant vascularization and rapid ingrowth of native tissue -Innovative breast implant technology designed to address a $3.0 billion market opportunity -Cash and cash equivalents balance as of September 30, 2024 was $15.4 million -Conference call to be held today at 10:00 a.m. U.S. EDT – REHOVOT, Israel , Nov. 27, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the third quarter ending September 30, 2024, and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel , Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant (CLGN) and Stratasys announce the initiation of a pre-clinical study to focus on the ability of implants to grow natural breast tissue and completely degrade over time.

CollPlant (CLGN), Stratasys Initiate Study for Breast Implants

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q2 2024 Earnings Conference Call August 20, 2024 10:00 AM ET Company Participants Dan Ferry - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Sean Lee - H.C.

CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript

- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin ® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter ended June 30, 2024, and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel & EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (Nasdaq: CLGN) and Stratasys Ltd. (Nasdaq: SSYS) today announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin® 3D printer. The collaboration between CollPlant and Stratasys is currently focused on the development of a bioprinting solution for CollPlant's breast implants, in a.

CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel , Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION

REHOVOT, Israel , July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023. The Company's first report details the initiatives that CollPlant has taken to adopt an ESG strategy with a focus on the pillars that represent the areas with the highest impact.

CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel , June 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced that it has successfully printed for the first-time breast implants of 200 cc, which are commercial size. These implants were printed using CollPlant's proprietary rhCollagen bioinks.

CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q1 2024 Results Conference Call May 29, 2024 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.

CollPlant Biotechnologies Ltd. (CLGN) Q1 2024 Earnings Call Transcript

Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel , May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced results for the first quarter ended 2024 and provided a corporate update.

CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update

-  Conference call to be held on Wednesday, May 29, 2024 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

CollPlant Biotechnologies (CLGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2023 Earnings Conference Call April 4, 2024 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Swayampakula Ramakanth - H.C.

CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript

Dermal filler program with AbbVie in clinical phase Regenerative breast implant program large-animal study underway to evaluate commercial-size implants with topline data expected in Q4 Ends 2023 with $26.7 million in cash and cash equivalents Conference call to be held on Thursday, April 4, 2024 at 10:00 a.m. U.S. EDT  REHOVOT, Israel, April 4, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

- Conference call to be held on Thursday, April 4, 2024, at 10:00 a.m. U.S. EDT - REHOVOT, Israel , March 26, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

REHOVOT, Israel , Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal. View as PDF Dear Shareholders, As we look toward a promising and exciting year ahead, I am proud to reflect on CollPlant's main achievements throughout 2023.

CollPlant Issues Letter to Shareholders

REHOVOT, Israel , Jan. 8, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq:  CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that Mr. Yehiel Tal, the Company's CEO, will participate in the Octane Aesthetic Tech Forum, being held on January 25-26, 2024 in Newport Beach, CA.

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California

The current market for breast implants is estimated at $2.6 billion a year CollPlant expects the study to conclude by the first half of 2024 CollPlant plans to use findings from this study and successive studies during 2024 for further optimization of the implant design towards a GLP preclinical pivotal study with commercial size implants REHOVOT, Israel , Jan. 2, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced its initiation of a pre-clinical trial to evaluate commercial-size, 3D-bioprinted, regenerative breast implants. Currently, there are no commercial products that allow regeneration of soft tissues such as the breast.

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Dory Kurowski - Investor Relations Yehiel Tal - Chief Executive Officer Eran Rotem - Deputy Chief Executive Officer and Chief Financial Officer Conference Call Participants Ben Haynor - Alliance Global Partners Operator Greetings.

CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript

Received a $10 million milestone payment in the third quarter from partner, AbbVie Inc., for achieving a major milestone in the second quarter in accordance with the strategic collaboration agreement related to the clinical-phase dermal filler product candidate Company is preparing to launch large-animal study with a commercial size breast implant by year-end Cash and cash equivalents totaled $29 million as of September 30, 2023, representing an estimated cash runway of at least two years Revenues of $10.7 million and operating loss of $2.4 million for the first nine months of 2023 Conference call to be held on November 29, 2023, at 10:00 am U.S. ET; Dial-in information herein REHOVOT, Israel , Nov. 29, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update on its programs. "This quarter, we continued to steadily advance our programs with modest cash use," said CollPlant's Chief Executive Officer, Yehiel Tal.

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

-  Conference call to be held on Wednesday, November 29, 2023 at 10:00 a.m. U.S. EDT - REHOVOT, Israel , Nov. 9, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it will report financial results for the third quarter of 2023 on Wednesday, November 29, 2023, before the market open.

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

-  Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Potential Products - REHOVOT, Israel , Nov. 1, 2023 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that the U.S. Patent and Trademark Office has granted a patent that covers CollPlant's photocurable dermal filler product candidate, being developed for the aesthetics market. U.S. Patent No.

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

- As a new participant, the Company strengthens its commitment to operate sustainably and transition the regenerative and aesthetics medicine industry to sustainable alternatives - REHOVOT, Israel , Sept. 21, 2023 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced that it has joined the United Nations Global Compact, the world's largest initiative for sustainable and responsible corporate governance.

News for CollPlant Biotechnologies Ltd - ADR Stock (CLGN)